Gilead Sciences Inc - Company Profile
Powered by
All the data and insights you need on Gilead Sciences Inc in one report.
- Save hours of research time and resources with
our up-to-date Gilead Sciences Inc Strategy Report
- Understand Gilead Sciences Inc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Related keylists
View moreGilead Sciences Inc (Gilead) is a research-based biopharmaceutical company. It is engaged in the discovery, development and commercialization of medicines for the treatment of cardiovascular, hematological and respiratory diseases, inflammation, liver diseases, cancer, and human immunodeficiency virus (HIV) infection. The company sells its products through subsidiaries and distributors in Europe, the Americas, Asia-Pacific, the Middle East and Africa. It has manufacturing facilities in Edmonton, Alberta, Canada; Foster City, San Dimas, Oceanside, California; and Cork, Ireland among others. The company has partnerships with universities, medical research institutions and global pharmaceutical leaders to develop new drugs. Gilead is headquartered in Foster City, California, the US.
Gilead Sciences Inc premium industry data and analytics
Products and Services
Products | Brands |
---|---|
HIV/AIDS | AmBisome |
Atripla | Atripla |
Biktarvy | Biktarvy |
XYZ | XYZ |
XYZ | XYZ |
XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
Year | Event | Description |
---|---|---|
2024 | Contracts/Agreements | In March, the company entered into a partnership with Merus N.V. to explore and identify novel dual tumor-associated antigens (TAA). |
2024 | Contracts/Agreements | In February, the company entered into an agreement with Launch Therapeutics to create a Joint Steering Committee throughout development. |
2024 | Contracts/Agreements | In February, the company and Biocytogen entered into an agreement to leverage the discovery and development of new antibody therapeutics. |
Competitor Comparison
Key Parameters | Gilead Sciences Inc | Merck & Co Inc | Pfizer Inc | Novartis AG | Abbott Laboratories |
---|---|---|---|---|---|
Headquarters | United States of America | United States of America | United States of America | Switzerland | United States of America |
City | Foster City | Kenilworth | New York | Basel | Abbott Park |
State/Province | California | New Jersey | New York | - | Illinois |
No. of Employees | 18,000 | 72,000 | 88,000 | 76,057 | 114,000 |
Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
Name | Position | Board | Since | Age |
---|---|---|---|---|
Daniel P. O’Day | Chief Executive Officer; Chairman | Executive Board | 2019 | 57 |
Andrew D. Dickinson | Chief Financial Officer | Senior Management | 2016 | 52 |
Diane E. Wilfong | Senior Vice President; Chief Accounting Officer | Senior Management | 2016 | - |
Merdad V. Parsey, M.D., Ph.D. | Chief Medical Officer | Senior Management | 2019 | 59 |
Johanna Mercier | Chief Commercial Officer | Senior Management | 2019 | 52 |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward